FATE - Fate up 5% after hours on interim phase 1 data on B-cell lymphoma candidate

Shares of Fate Therapeutics (NASDAQ:FATE) are up 5% after hours after presenting interim, early-stage data from FT596, an off-the-shelf, iPSC-derived natural killer ("NK") cell candidate for B-cell lymphoma. Five of six patients achieved a complete response with a single dose (900M cells) in combination with rituximab. Objective response was seen in 13 of 19 patients with a single dose at either 90M or 300M cells. Ten out of 11 patients who received a second cycle continue to have an ongoing response. No dose-limiting toxicities were observed. Results were presented at the American Society of Hematology Annual Meeting. #ASH2021 Read what Citi and Cowen had to say about Fate recently.

For further details see:

Fate up 5% after hours on interim phase 1 data on B-cell lymphoma candidate